RABEP2

Across TCGA pan-cancer cohorts, RABEP2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of RABEP2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RABEP2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RABEP2 is over-expressed in tumor.

BLCA, LIHC, and HNSC are the cancer types where RABEP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RABEP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.567	<.001	11	view →
LIHC	Female	II,III,IV	+1.445	<.001	8	view →
HNSC	Male	III,IV	+0.612	<.001	8	view →
STAD	All	II,III,IV	+0.924	<.001	7	view →
KIRP	All	II,III,IV	+0.578	.001	7	view →
BRCA	All	III,IV	+0.944	<.001	6	view →
UCEC	All	All	+0.732	<.001	6	view →
COAD	All	All	+0.388	<.001	6	view →
CHOL	Female	All	+2.629	<.001	5	view →
KICH	Female	All	+0.555	.008	4	view →
LUAD	Female	All	+0.297	.007	4	view →
PRAD	All	All	+0.779	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

RABEP2–BLCA

Open the BLCA breakdown →